AstraZeneca stock falls after FDA panel votes against new cancer drug
Summary
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.